Table 2 Stratified pooled odds ratios and 95% confidence intervals of NSAIDs intake and prostate cancer
From: Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk
Subgroup | Number of studies | Odds ratio (95% confidence interval) | Heterogeneity | |
|---|---|---|---|---|
| Â | Â | Â | P | I2(%) |
Aspirin | Â | Â | Â | Â |
USA | 14 | 0.937 (0.900, 0.975) | 0.012 | 52.0 |
Other countries | 10 | 0.969 (0.934, 1.006) | 0.000 | 70.0 |
Cohort studies | 13 | 0.930 (0.894, 0.967) | 0.025 | 48.6 |
Case-control studies | 11 | 0.976 (0.940, 1.013) | 0.000 | 69.0 |
NSAIDs | Â | Â | Â | Â |
USA | 3 | 0.922 (0.836, 1.016) | 0.011 | 77.7 |
Other countries | 8 | 1.212 (1.174, 1.251) | 0.000 | 92.7 |
Cohort studies | 4 | 1.022 (0.938, 1.113) | 0.000 | 90.2 |
Case-control studies | 7 | 1.205 (1.167, 1.245) | 0.000 | 93.3 |
NA-NSAIDs | Â | Â | Â | Â |
USA | 6 | 1.009 (0.927, 1.099) | 0.807 | 0.0 |
Other countries | 8 | 0.915 (0.869, 0.964) | 0.001 | 70.3 |
Cohort studies | 5 | 0.992 (0.909, 1.083) | 0.629 | 0.0 |
Case-control studies | 9 | 0.922 (0.876, 0.971) | 0.002 | 67.9 |